- Home
- DCOM vs INBX Comparison
DCOM vs INBX Comparison
Compare DCOM & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | INBX |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 2024 |
Fundamental Metrics
Financial Performance| Metric | DCOM | INBX |
|---|---|---|
| Price | $42.80 | $71.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $47.80 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 396.4K | 253.8K |
| Earning Date | 10-20-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 329.09 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $19,907,000.00 | $1,300,000.00 |
| Revenue This Year | $16.16 | N/A |
| Revenue Next Year | $14.21 | N/A |
| P/E Ratio | $28.04 | ★ N/A |
| Revenue Growth | 19.03 | ★ 550.00 |
| 52 Week Low | $25.63 | $57.30 |
| 52 Week High | $43.38 | $155.29 |
Technical Indicators
Market Signals| Indicator | DCOM | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 31.40 |
| Support Level | $39.64 | $57.30 |
| Resistance Level | $43.38 | $86.61 |
| Average True Range (ATR) | 1.06 | 7.16 |
| MACD | 0.28 | -1.90 |
| Stochastic Oscillator | 89.18 | 16.14 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.